(Reuters) – Regeneron Pharmaceuticals reported better-than-expected revenue aided by sales from its COVID-19 antibody outside the United States and strong demand for its blockbuster drugs Dupixent and Eylea.
About $216 million in first-quarter sales from the intravenous COVID drug through a partnership with Roche, which sells the drug outside the United States under brand name Ronapreve, helped Regeneron limit the setback from no sales in the United States – its biggest market.
Regeneron in February warned it will record zero sales from the intravenous COVID drug in the United States for the first quarter after the U.S. Food and Drug Administration limited its use due to lack of effectiveness against the Omicron coronavirus variant.
The drugmaker is now working on experimental “next generation” antibodies that are tailored against variants including those of Omicron-lineage.
It was the revenue from Roche collaboration that helped in the topline beat, Wells Fargo analyst Mohit Bansal said in a note.
Shares of Regeneron were marginally up at $668 in premarket trade, after the company said its overall sales grew 17% to $2.97 billion in the first quarter, which was higher than the average analyst estimate of $2.72 billion, as per Refinitiv IBES data.
Eczema treatment Dupixent and macular degeneration drug Eylea recorded sales growth of 11% and 43%, respectively.
They have been key drivers for the company’s earnings growth, and the company and analysts are both optimistic about further growth for the two drugs.
Regeneron’s French partner Sanofi SA, which records the sales from Dupixent, raised its peak sales target for Dupixent to more than 13 billion euros ($14.3 billion) in late March.
Regeneron’s net profit in the quarter ended March 31 fell 13% to $974 million from a year earlier.
(This story corrects to say “intravenous COVID drug”, not “COVID pill”, in paragraph 2 and 3. The error was repeated in a previous version of the story)
(Reporting by Leroy Leo in Bengaluru; Editing by Rashmi Aich and Shinjini Ganguli)